However, whilst the goal of achieving a potent dual Bcl-2/Bcl-xL inhibitor with activity across a broad range of tumour types with manageable thrombocytopenia risk was achieved dose limiting cardiovascular toxicity was observed during preclinical development thus AZD4320 could not be progressed to the clinic. This evidence concerns the gene BCL2L1 and Thrombocytopenia.